Celgene (CELG) Tops Q2 EPS by 4c, Raise FY EPS Guiadnce

Celgene (CELG) PT Raised to $160 at BMO Capital; 'Revlimid Gaining Traction in Europe... Growth Should Accelerate Through 2017'

BMO Capital raised its price target on Celgene (NASDAQ: CELG) to $160.00 (from $152.00) while maintaining a Outperform rating, following a review Revlimind's outlook in the U.S. and Europe.

Analyst M. Ian Somaiya notes a positive outlook on Revlimind, suggesting the drug's growth could accelerate into... More

Celgene (CELG) PT Raised to $160 at Leerink Partners Following 2Q Report

Leerink Partners raised its price target on Celgene (NASDAQ: CELG) to $160.00 (from $150.00) while maintaining a Outperform rating. CELG announced 2Q financial results with positive underlying fundamentals Total revenues of $3,268mm beat consensus by 1%. Celgenes reported Q2 pro forma EPS of $1.82, 1% above recent... More

Stifel Resumes Celgene (CELG) at Buy

Stifel resumes coverage on Celgene (NASDAQ: CELG) with a Buy rating and a price target of $155.00.

Analyst Thomas Shrader said 2Q showed no signs that Revlimid growth in MM will level.

"Based principally on Revlimid, Celgene estimates it will... More

Celgene (CELG) Investors Can Shift Focus to 2nd-Half Milestones Following Solid Print - Cowen

Cowen analyst Eric Schmidt reiterated an Outperform rating and $150 price target on Celgene (NASDAQ: CELG) following "solid" Q2 results. Schmidt said the attention shifts to 2nd-half milestones after confidence was regained in Otezla.

"Importantly, Otezla rebounded following a weak Q1. Celgene's IMiD... More

Celgene (CELG) PT Raised to $175 at Oppenheimer

Oppenheimer analyst Leah Rush Cann raised her price target on Celgene (NASDAQ: CELG) to $175.00 (from $148.00) while maintaining an Outperform rating following "impressive" Q2 results.

Cann cited higher than expected Otezla and Revlimid sales, While R&D expenses of $835 million were lower than the... More